The company teaching drug factories to think - one batch, one deviation, one prediction at a time.
ABOVE: The Aizon wordmark and its sparked "a." Behind the mark is a deliberately narrow idea - build AI for exactly one industry, pharmaceutical manufacturing, and refuse the temptation to broaden.
Most artificial-intelligence companies want to be everywhere at once. Aizon went the other direction. The San Francisco software firm - founded in 2014 and known for its first several years as Bigfinite - builds AI for a single, unglamorous, heavily regulated corner of the economy: the factories where medicines are made.
That focus is the whole strategy. Pharmaceutical and biotech manufacturing runs on rules. Every batch of a drug must be documented, reviewed and released under Good Manufacturing Practice, the family of regulations shorthanded as GxP. A generic dashboard that works for a logistics firm or a bank cannot simply be pointed at a bioreactor and trusted. Aizon's pitch is that it starts from the regulation rather than bolting compliance on afterward.
The company describes itself in a single, telling sentence: "We are pharma manufacturing professionals well-versed in technology - not the other way around." It is a small line that explains a lot about why the product looks the way it does.
A modern drug plant generates enormous amounts of data - from process historians, sensors, quality systems and paper-derived batch records - but that data usually sits in silos and speaks different dialects. When something goes wrong, or when a batch needs releasing, teams stitch the picture together by hand. Reviews that gate a product's release can stretch across days.
Aizon's answer is to contextualize all of that production data around the batch, then layer analytics on top. Its platform aims to give quality, production and technical-operations leaders real-time visibility, predictive warnings before deviations happen, and - most recently - agentic AI that can generate insight and take steps on its own. The stated ambition, aired in a 2025 webinar, is to compress batch release "from days to seconds."
Aizon's suite is modular. The data layer comes first - because, as the company likes to note, you cannot predict a yield you cannot see.
An AI-powered intelligent lakehouse that integrates unlimited structured and unstructured sources and contextualizes production data around the batch - enabling digital batch review, real-time monitoring and batch comparison.
An intelligent/electronic batch record (iBR/eBR) product that converts master batch records into executable recipes and applies AI to batch processing on the shop floor.
Machine-learning models aimed squarely at yield optimization and deviation reduction inside GxP-regulated manufacturing.
A natural-language application and dashboard builder that lets manufacturing teams create self-service insights and apps without writing code.
Wrapping it all is Aizon Consulting Services - implementation and strategy support the company says is designed to deliver first results in roughly six weeks.
We are pharma manufacturing professionals well-versed in technology - not the other way around.
Aizon competes in a crowded manufacturing-intelligence market that includes MES and analytics vendors like Siemens Opcenter, Körber's PAS-X, Rockwell PharmaSuite, Tulip, Seeq and Sight Machine, plus general-purpose industrial-AI and lakehouse platforms. Its wedge is depth: everything is designed GxP-first, for one industry, so quality and regulatory teams have less to validate and less to distrust.
Bars are illustrative of Aizon's positioning claims, not independent benchmarks.
Toni Manzano, Pep Gubau and Pere Merino launch the company to bring big data and AI to pharma and biotech.
A seed round supports the build-out of the GxP data and analytics platform.
Bigfinite becomes Aizon, sharpening its identity around AI for pharmaceutical manufacturing.
NewVale Capital leads a round to scale the platform and advance a next-generation electronic batch record.
Aizon reveals an agentic upgrade to its core platform - a shift from data management toward autonomous insight and execution.
The new features become available to all customers in early Q1 2026.
"This investment validates our platform's success and equips us to realize our strategic objectives better."
"We're excited to contribute to Aizon's new chapter as it redefines pharmaceutical manufacturing with AI-driven solutions."
Aizon builds GxP-compliant AI software for pharmaceutical and biotech manufacturing - running electronic batch records, monitoring processes in real time, and using predictive and agentic AI to improve yield, cut deviations and ensure product quality.
Yes. It was originally founded as Bigfinite before rebranding to Aizon to focus on AI for pharma manufacturing.
It was founded around 2014 by Toni Manzano, Pep Gubau and Pere Merino. It is headquartered in San Francisco, with a major office in Barcelona, Spain.
Roughly $44.78M in total, including a $20M Series C in February 2024 led by NewVale Capital, with Atlantic Bridge, Crosslink Capital and Uncork Capital participating.
Aizon Unify (data lakehouse and batch review), Aizon Execute (electronic batch records), Aizon Predict (predictive ML) and Aizon Agentic Studio (no-code, natural-language app builder), plus consulting services.